02552 HUA MEDICINE-B
- 1.310
- -0.020-1.50%
HUA MEDICINE-B News
HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.
HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hualing Pharmaceutical announced the successful completion of Phase I clinical trials for its second-generation glucokinase activator conducted in the usa.
Shanghai, November 30, 2024 /PRNewswire/ -- Hualing Pharmaceutical ("the company", Hong Kong Stock Exchange stock code: 2552.HK) today announced at the 9th China BioMed Innovation and Investment Conference (CBIIC) that it has successfully completed the Phase Ia clinical study of the second-generation glucose kinase activator (GKA) conducted in the USA. The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) is
Hua Ling Pharmaceuticals announces the successful completion of the SENSITIZE study conducted in hong kong, china.
On November 30, 2024, shanghai /美通社/ -- china meheco group ("company", Stock code: 2552.HK on the Hong Kong Stock Exchange) announced today at the 9th China BioMed Innovation and Investment Conference (CBIIC) that the company has successfully completed the SENSITIZE research in collaboration with Professor Juliana Chan's team at the Chinese University of Hong Kong, aiming to improve β cell function using DPP-4 Inhibitors.
Hualead Pharmaceuticals-B (02552): Termination of Bayer Hofmann's agency sales rights from January 1, 2025.
Hua Ling Medicine-B (02552) announced that the company has sent a written notice to Bayer Healthcare LLC, indicating its intention to transfer the commercialization responsibility of the innovative glucose kinase activator, Huatangning, developed for the treatment of type 2 diabetes in china, to the company starting from January 1, 2025.
Hua Ling Pharmaceutical (02552) to regain commercialization rights of Hua Tangning from Bayer Pharmaceutical Company in China.
Gold Summit Financial News | Hualing Medicine (02552) announced that on November 21, 2024, its wholly-owned subsidiary Hualing shanghai issued a written notice to Bayer Healthcare Co., Ltd., indicating the intention to transition the commercialization responsibility of the company's original glucose kinase activator Huatingning (dorzagliatin tablets) for the treatment of type 2 diabetes in china to the company starting from January 1, 2025. On August 17, 2020, the parties involved established a cooperative relationship for the commercialization of Huatingning in china and signed a related exclusive promotion service agreement. According to the agreement, Bayer obtained the rights to Huatingning in china.
Hua Medicine Terminates Commercialization Agreement With Bayer for Type 2 Diabetes Treatment
Hua Ling Pharmaceuticals-B (02552.HK) announced the commercial transition of Huatangning, opening up a new market strategy.
Gelonghui November 22nd | Huali Pharma-B (02552.HK) announced that on November 21, 2024, its wholly-owned subsidiary Huali Pharma Technology (Shanghai) Co., Ltd. ("Huali Shanghai") issued a written notice to Bayer Healthcare Co., Ltd. ("Bayer"), expressing its intention to transition the commercialization responsibility of the company's first-in-class glucose kinase activator dorzagliatin tablets for the treatment of type 2 diabetes in China to the company from January 1, 2025. On August 17, 2020, the relevant parties established the commercialization of dorzagliatin in China.
HUA MEDICINE-B: INTERIM REPORT 2024
A visual guide to understanding the 2024 interim report of Hualing Pharmaceuticals-B (02552.HK)
On August 29, Hualing Pharmaceuticals-B(02552.HK) released its 2024 interim report. The following infographic will help you understand it.
Express News | Hua Medicine H1 Pretax Profit RMB -142.2 Million
Express News | Hua Medicine H1 Revenue RMB 102.7 Million
HUA MEDICINE-B: INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2024
Hualing Pharmaceuticals-B (02552.HK) held a board of directors meeting on August 29 to consider and approve the mid-term performance.
China State-Owned Enterprise Hualing Pharmaceutical (02552.HK) announced that the board of directors meeting will be held on Thursday, August 29, 2024 to consider and approve the interim performance of the group ending on June 30, 2024, and related announcements, as well as to deal with other matters.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Hualing Pharmaceuticals announced at the 2024 ADA Scientific Conference the potential of using Dapagliflozin in combination with SGLT-2 inhibitors.
Shanghai, June 24, 2024 / PRNewswire / - Hualei Medicine ("the Company", Stock Code: 2552.HK) announced today that it demonstrated multiple basic research results at the 84th American Diabetes Association (ADA) Scientific Sessions, including pioneering innovative drugs GKA Duvoglitazone which reduces blood glucose levels by promoting the secretion of insulin and GLP-1 through dual activation of glucose kinase. Duvoglitazone and SGLT-2 inhibitor Caglitinib are used in combination. This research was conducted by the Company and its wholly-owned subsidiary, Nanjing Shengderui'er Pharmaceutical Technology Co., Ltd. (Shengderui'er).
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) CEO Compensation Is Looking A Bit Stretched At The Moment
HKEX Buzz: Hualei Pharmaceutical-B (02552) rose more than 4% and will exhibit multiple research achievements at the American Diabetes Association conference in 2024.
Hua Ling Pharmaceutical - B (02552) rose more than 4%, as of the time of publication, up 4.43% to HKD 1.65, with a turnover of HKD 1.684 million.
No Data
